CN103479599A - 一种盐酸伐昔洛韦胶囊制剂及其制备方法 - Google Patents
一种盐酸伐昔洛韦胶囊制剂及其制备方法 Download PDFInfo
- Publication number
- CN103479599A CN103479599A CN201310424526.8A CN201310424526A CN103479599A CN 103479599 A CN103479599 A CN 103479599A CN 201310424526 A CN201310424526 A CN 201310424526A CN 103479599 A CN103479599 A CN 103479599A
- Authority
- CN
- China
- Prior art keywords
- valaciclovir hydrochlordide
- valaciclovir
- hydrochlordide
- preparation
- capsule preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 239000002775 capsule Substances 0.000 title claims abstract description 42
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 title abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000003756 stirring Methods 0.000 claims abstract description 23
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 20
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 20
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 20
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 230000003292 diminished effect Effects 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 11
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 62
- 229940093257 valacyclovir Drugs 0.000 claims description 62
- 238000010792 warming Methods 0.000 claims description 20
- 239000006187 pill Substances 0.000 claims description 17
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical group CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 10
- PRXRUNOAOLTIEF-WUOFIQDXSA-N sorbitan trioleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C\CCCCCCCC)C1OCC(O)C1OC(=O)CCCCCCC\C=C\CCCCCCCC PRXRUNOAOLTIEF-WUOFIQDXSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract 3
- 239000012730 sustained-release form Substances 0.000 abstract 3
- 239000008188 pellet Substances 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 238000009413 insulation Methods 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 8
- 229960004150 aciclovir Drugs 0.000 description 6
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- -1 ACV-TP ester Chemical class 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- PGSPUKDWUHBDKJ-UHFFFAOYSA-N 6,7-dihydro-3h-purin-2-amine Chemical compound C1NC(N)=NC2=C1NC=N2 PGSPUKDWUHBDKJ-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品 | 1.5h释放度(%) | 3h释放度(%) | 8h释放度(%) |
实施例1 | 29.8 | 61.5 | 99.3 |
实施例2 | 16.5 | 31.8 | 75.6 |
实施例3 | 22.3 | 52.8 | 99.7 |
对比实施例1 | 67.3 | 96.7 | 100.5 |
对比实施例2 | 43.6 | 86.9 | 98.5 |
对比实施例3 | 23.6 | 88.1 | 99.8 |
对比实施例4 | 68.1 | 89.7 | 99.4 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310424526.8A CN103479599B (zh) | 2013-09-18 | 2013-09-18 | 一种盐酸伐昔洛韦胶囊制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310424526.8A CN103479599B (zh) | 2013-09-18 | 2013-09-18 | 一种盐酸伐昔洛韦胶囊制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103479599A true CN103479599A (zh) | 2014-01-01 |
CN103479599B CN103479599B (zh) | 2015-12-09 |
Family
ID=49820425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310424526.8A Expired - Fee Related CN103479599B (zh) | 2013-09-18 | 2013-09-18 | 一种盐酸伐昔洛韦胶囊制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103479599B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114621227A (zh) * | 2022-02-28 | 2022-06-14 | 海南久常制药有限公司 | 一种盐酸伐昔洛韦、制剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101502521A (zh) * | 2008-09-04 | 2009-08-12 | 山东淄博新达制药有限公司 | 阿昔洛韦缓释制剂组合物及其制备方法 |
-
2013
- 2013-09-18 CN CN201310424526.8A patent/CN103479599B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101502521A (zh) * | 2008-09-04 | 2009-08-12 | 山东淄博新达制药有限公司 | 阿昔洛韦缓释制剂组合物及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114621227A (zh) * | 2022-02-28 | 2022-06-14 | 海南久常制药有限公司 | 一种盐酸伐昔洛韦、制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103479599B (zh) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102379853B (zh) | 一种单磷酸阿糖腺苷冻干粉针剂及其制备方法 | |
CN103864819A (zh) | 一种头孢他啶化合物及其药物组合物 | |
CN101904825B (zh) | 泛昔洛韦分散片及其制备方法 | |
CN104458924B (zh) | 一种含有亲水凝胶骨架材料的制剂中有关物质的检测方法 | |
CN106137971A (zh) | 一种他克莫司分散体及其缓释组合物及制备方法 | |
CN101502521A (zh) | 阿昔洛韦缓释制剂组合物及其制备方法 | |
CN103479599B (zh) | 一种盐酸伐昔洛韦胶囊制剂及其制备方法 | |
CN104188928B (zh) | 一种盐酸伐昔洛韦片剂及其制备方法 | |
CN101843624B (zh) | 一种用于治疗畜禽球虫病的可溶性粉剂的制备方法 | |
CN104069068B (zh) | 炔丙基半胱氨酸固体分散体及其制备方法和用途 | |
CN103301089B (zh) | 一种泛昔洛韦胶囊制剂及其制备方法 | |
CN102321007A (zh) | 一种奥拉西坦化合物、制备方法及其药物组合物 | |
CN103980279B (zh) | 一种甲氨蝶呤化合物及注射用甲氨蝶呤 | |
CN103040855A (zh) | 一种磷酸氟达拉滨的药物组合物及其制备方法 | |
CN107137360A (zh) | 一种注射用阿扎胞苷冻干制剂 | |
CN103304566A (zh) | 一种新的结晶型恩替卡韦 | |
CN106943356B (zh) | 一种泛昔洛韦缓释颗粒剂及其制备方法 | |
CN105541945B (zh) | 一种单磷酸阿糖腺苷晶型化合物 | |
CN103462931A (zh) | 一种阿昔洛韦胶囊制剂及其制备方法 | |
CN100506212C (zh) | 一种注射用去甲斑蝥酸钠冻干粉及其制备方法 | |
CN102988402A (zh) | 一种含有环磷腺苷化合物药物组合物及其制备方法 | |
CN103462930B (zh) | 一种更昔洛韦胶囊制剂及其制备方法 | |
CN107536831A (zh) | 一种含维格列汀与二甲双胍的组合物及制备方法 | |
CN102552210B (zh) | 一种恩替卡韦胶囊组合物及其制备方法 | |
CN108721222B (zh) | 一种注射用阿扎胞苷冻干粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Yu Yanyan Inventor before: The inventor has waived the right to be mentioned |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151030 Address after: 211200 Lishui Economic Development Zone, Jiangsu, Nanjing No. 1 Shandong Road Applicant after: Nanjing Zhengkuan Pharmaceutical Science and Technology Co., Ltd. Address before: Lishui Economic Development Zone, Nanjing City, Jiangsu province 211200 zhe Ning Road No. 369 Applicant before: Nanjing Zhengliang Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171222 Address after: 100037 room 1674A, No. 1, Fucheng door street, Xicheng District, Beijing Patentee after: Beijing is standing grain profit and Pharmaceutical Technology Co., Ltd too Address before: 211200 Lishui Economic Development Zone, Jiangsu, Nanjing No. 1 Shandong Road Patentee before: Nanjing Zhengkuan Pharmaceutical Science and Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151209 Termination date: 20200918 |